Navigation Links
ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Date:3/18/2011

e submitted in the MAA as insufficient or inconclusive, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, deny the approval of Cinryze for acute treatment and / or prevention of HAE or approve a competing product which has been granted orphan drug designation thereby preventing Cinryze from reaching the European market.  In addition, the EMEA has enacted orphan drug legislation and Cinryze has received an orphan drug designation under this legislation. The EMA must reconfirm the orphan designation in connection with the approval of an MAA.  These factors, and other factors, including, but not limited to those described in our annual report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release are made as of the date hereof and may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. These forward looking statements should not be relied upon as representing our assessments as of any date subsequent to the date of this press release.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... -- Norgine B.V. today announced that the ... preparation, NER1006, presented at the 79 th Annual ... Philadelphia, PA , has met its ... endpoint of cleansing success. The study demonstrated high quality ... in screening colonoscopy patients. [1] (Logo: ...
(Date:10/19/2014)... 19, 2014  Henry Schein, Inc. (NASDAQ: ... products and services to office-based dental, animal health and ... Iwase Dental Supply, Inc., a leading full-service provider of ... Henry Schein,s entrance into Japan , ... increases to 28 the number of countries in which ...
(Date:10/17/2014)... , Oct. 17, 2014  Training market ... a critical success factor in today,s highly competitive ... market research organizations that effectively and efficiently produce ... or service area. Effective training ... and earn recognition from internal clients by developing ...
Breaking Medicine Technology:Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2
... SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- ... studies of the,investigational medication guanfacine extended release ... agonist. These data from two short-term phase,III ... studies, presented at the 2007 American Psychiatric,Association ...
... Inc.,(Nasdaq: IMGN), a biopharmaceutical company that develops targeted,anticancer ... that clinical findings for three,different TAP compounds for ... at the 43rd American Society of Clinical Oncology ... in Chicago, IL., Trastuzumab-DM1 (abstract #1042) , "A ...
Cached Medicine Technology:Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 2Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 3Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 4Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 5Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 6Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 7Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 8ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 2ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 3
(Date:10/20/2014)... October 20, 2014 Zereana Jess-Huff, a 34-year-old ... Maryland 2014 on a platform to think outside the bra. ... uses her position to raise awareness about women’s other lady ... breast cancer. You say the color pink and everybody knows ... for a fact that it has not been won when ...
(Date:10/20/2014)... October 20, 2014 AttorneyOne.com, a recognized authority ... information from the FDA on Sit and Slim II ... not to purchase or use Sit and Slim II because ... II is promoted as weight loss product on various websites ... the market in 2010 for safety reasons, can significantly increase ...
(Date:10/20/2014)... 2014 Based on a proprietary ... imaging assays capable of determining DNA sequence, location ... these three dimensions of high-resolution data, dGH assays ... widest range of disease-causing genetic rearrangements, including chromosomal ... genomic tools, including today’s advanced sequencing technologies. , ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live ... the world, it’s a reality. And while new shoes are ... to walk barefoot on rocky terrain or sewage-lined streets just ... friends. , Buckner International's Shoes for Orphan Souls ... October to encourage support for Air1 and while also providing ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal ... throughout the greater Phoenix area and across Arizona reports ... to catastrophic automobile accidents. Statistics have indicated a steady ... Arizona. As such, Hastings and Hastings has seen a ... those who have been injured through no fault of ...
Breaking Medicine News(10 mins):Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3
... , MONDAY, June 27 (HealthDay News) -- Pregnancy is ... says. Canadian researchers analyzed 432 births to women with ... the province of British Columbia between 1998 and 2009. They ... birth weight between babies born to women with MS and ...
... Dr Frank McKeon, Senior Group Leader of the Stem ... Singapore (GIS), and Principal Investigator Dr Wa Xian at ... counterparts from the Harvard Medical School, the Brigham and ... Singapore, have made the striking finding that Barrett,s esophagus[1] ...
... in our mouths use to invade heart tissue, causing a dangerous ... work raises the possibility of creating a screening tool perhaps ... gauge a dental patient,s vulnerability to the condition. The identification ... a foothold in heart tissue is reported in the June issue ...
... Babies born prematurely could be at greater risk of ... landmark study investigating the impacts of preterm birth on ... identifying new strategies for minimising the consequences of being ... of births each year in Australia. By comparing ...
... 27, 2011 A simple roll of duct tape has ... time-consuming problem of communicating with hospital patients who are isolated ... system saved up to 2,700 hours and $110,000 a year ... of red duct tape extending from the threshold of the ...
... Canadian researchers have found that maternal multiple sclerosis (MS) ... risk to their offspring. Full findings now appear in ... Wiley-Blackwell on behalf of the American Neurological Association. ... the most common cause of non-traumatic neurological disability in ...
Cached Medicine News:Health News:Scientists identify a novel mechanism for evolution of highly aggressive cancers 2Health News:Scientists identify a novel mechanism for evolution of highly aggressive cancers 3Health News:How cavity-causing microbes invade heart 2Health News:How cavity-causing microbes invade heart 3Health News:Helping preterm babies get the best start 2Health News:Innovative duct tape strategy saves hospitals time, money; improves infection prevention 2Health News:Study finds pregnancy safe in multiple sclerosis 2
A lower cost alternative to the flagship A3, the A1 retains the essential characteristics of high quality image, simplicity of operation and reliability....
... highly sensitive DR system. It features a ... is designed for most general radiographic applications. ... wall stand and table configurations. , ... produces detailed patient images with reduced dose. ...
... ulitizes ultrasonic waves to remove bone cement speedily ... probe liquifies the cement at the point of ... , ,A special feature of the apparatus is ... to signal this to the operator instantly. Probe ...
Provides stable positioning of the knee during surgery....
Medicine Products: